Señales en vivo de SANION.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:23):

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark...

Stats
Volumen de hoy	386 306
Volumen promedio	395 716
Capitalización de mercado	206.68M
EPS	SEK0 ( 2024-02-28 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-29
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.290
ATR14	SEK0.0130 (0.70%)

Volumen Correlación

Largo: 0.16 (neutral)

Corto: -0.25 (neutral)

Signal:(60.281) Neutral

Saniona AB (publ) Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Saniona AB (publ) Correlación - Moneda/Commodity

-0.04
( neutral )

-0.47
( neutral )

0.00
( neutral )

-0.59
( weak negative )

0.00
( neutral )

0.42
( neutral )

Saniona AB (publ) Finanzas

Annual	2023
Ingresos:	SEK16.84M
Beneficio Bruto:	SEK-79.35M (-471.18 %)
EPS:	SEK-1.290

FY	2023
Ingresos:	SEK16.84M
Beneficio Bruto:	SEK-79.35M (-471.18 %)
EPS:	SEK-1.290

FY	2022
Ingresos:	SEK15.28M
Beneficio Bruto:	SEK10.81M (70.72 %)
EPS:	SEK-3.33

FY	2021
Ingresos:	SEK10.48M
Beneficio Bruto:	SEK5.85M (55.81 %)
EPS:	SEK-6.59

Financial Reports:

No articles found.

Saniona AB (publ)

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.